TY  - JOUR
AU  - Ahn, JS
AU  - Lin, J
AU  - Ogawa, S
AU  - Yuan, C
AU  - O'Brien, T
AU  - Le, BHC
AU  - Bothwell, AM
AU  - Moon, H
AU  - Hadjiat, Y
AU  - Ganapathi, A
Y2  - 2020/12/21
Y1  - 2017/01/01
SN  - 1178-7090
UR  - http://hdl.handle.net/11343/256842
AB  - Treatment of cancer pain is generally based on the three-step World Health Organization (WHO) pain relief ladder, which utilizes a sequential approach with drugs of increasing potency. Goals of pain management include optimization of analgesia, optimization of activities of daily living, minimization of adverse effects, and avoidance of aberrant drug taking. In addition, it is recommended that analgesic regimens are individualized and simplified to help ensure patient compliance and should provide the least invasive, easiest, and safest route of opioid administration to ensure adequate analgesia. Buprenorphine and fentanyl are two opioids available for the relief of moderate-to-severe cancer pain. Available clinical data regarding the transdermal (TD) formulations of these opioids and the extent to which they fulfill the recommendations mentioned earlier are systematically reviewed, with the aim of providing additional information for oncologists and pain specialists regarding their comparative use. Due to lack of studies directly comparing TD buprenorphine with TD fentanyl, data comparing these with other step-3 opioids are also evaluated in a network fashion.
LA  - English
PB  - DOVE MEDICAL PRESS LTD
T1  - Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review
DO  - 10.2147/JPR.S140320
IS  - Journal of Pain Research
VL  - 10
SP  - 1963-1972
L1  - /bitstream/handle/11343/256842/PMC5571859.pdf?sequence=1&isAllowed=y
ER  -